San Francisco-based Kindred Bioscience did not meet the primary endpoint during a trial of CereKin, its drug for canine osteoarthritis, based off studies for Amgen and Pfizer's Enbrel.
Almost exactly one year after Daniel O'Connor was named CEO at Advaxis, he celebrated the personal milestone with the latest in a string of deals. Pharma giant Merck stepped up with a no-strings-attached immuno-oncology development pact for pembrolizumab, one of the hot new checkpoint inhibitors promising a groundbreaking new approach to treating a wide variety of cancers.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
German contract researcher Evotec has signed a deal with Medicines for Malaria Venture, lending its expertise to the nonprofit's efforts to encourage neglected disease R&D around the world.
Startup OncoSynergy is jumping on the crowdfunding bandwagon to raise money to test a drug candidate in its pipeline against the deadly Ebola virus, which has infected 2,473 people and killed 1,350 of those in the worst outbreak of the disease in West Africa.
Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.
Kinavet CA-1 drew FDA ire last month for bogus marketing claims, but the canine cancer drug, intended to treat mast cell tumors, has gone ahead to a Phase III clinical trial in Florida.
Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.
With media organizations broadcasting lurid images of the Liberian military's violent effort to enforce a quarantine in an effort to corral Ebola in the slums in Monrovia, the frenzy of attention continued to concentrate a spotlight on the sudden rush to get early-stage experimental treatments or vaccines to West Africa.
Amid a sea of companies creating mobile medical devices, a Philadelphia startup hopes to set itself apart and deliver an innovative product that provides quick, at-home lab diagnostics on a smartphone.